- TRADE NAMES: Cytadren (Novartis); Orimeten; Orimetene; Rodazol
- INDICATIONS: Suppression of adrenal function, metastatic carcinoma
- CLASS: Aromatase inhibitor
- HALF-LIFE: 7–15 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Betamethasone, Dexamethasone, Doxercalciferol, Oxtriphylline, Triamcinolone
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
